文献速递临床试验与 GCP流行病学与生物统计

管理住院临终患者不确定的康复:AMBER 照护集的混合方法可行性整群随机对照试验

Managing uncertain recovery for patients nearing the end of life in hospital: a mixed-methods feasibility cluster randomised controlled trial of the AMBER care bundle.
PubMed 文献 · Trials · 2019-08-16

这项前瞻性混合方法可行性整群随机对照试验评估了在英国医院使用的 AMBER 照护集。共筛查 894 例患者,招募 65 例(达招募目标的 81.3%),对照臂招募困难,728 例筛查者中 647 例(88.9%)被排除。作者结论为:完全试验在技术上可行,但因干预资格标准操作化存在根本问题而不切实际,需考虑替代研究方法。

要点

  • AMBER 照护集用于支持康复不确定的住院患者,尚未经随机对照试验评估。
  • 共招募 65 例患者,为招募目标 80 例的 81.3%,对照臂招募困难。
  • 作者认为完全试验技术上可行,但因资格标准操作化问题而不切实际。

核心结论

  • AMBER 照护集的完全试验在技术上可行,但因干预资格标准操作化存在根本问题而不切实际,该问题妨碍了最佳招募。
  • 鉴于该复杂干预仍在临床中使用并在政策中被倡导,必须考虑并测试替代研究方法。

研究设计与样本

  • 前瞻性混合方法可行性整群随机对照试验。
  • 定量数据来自患者(患者无决策能力时来自代理人),用于考察招募、保留和随访率,测试数据收集工具及最佳时机,测试识别财务资源使用的方法,并探索研究程序对医护人员和患者的可接受性。
  • 采用描述性统计分析和框架法的主题分析。

主要发现

  • 共筛查 894 例患者,其中 220 例符合条件,符合条件者中 19 例(8.6%)拒绝参与。
  • 对照臂招募困难:该臂筛查 728 例患者,647 例(88.9%)被排除。
  • 共招募 65 例患者(为招募目标 80 例的 81.3%)。
  • 许多患者为老年人(≥80 岁者占 46.2%,n=30,均值 77.8 岁,标准差 12.3 岁),53.8% 为非癌症诊断,平均 2.3 种合并症;24.6% 患者(n=16)在住院期间死亡,35.4%(n=23)在出院后 100 天内死亡。
  • 两个试验臂基线 IPOS 分量表评分均提示中度患者焦虑(对照臂:均值 13.3,标准差 4.8;干预臂:均值 13.3,标准差 5.1),howRwe 提示良好照护体验(对照臂:均值 13.1,标准差 2.5;干预臂:均值 11.5,标准差 2.1)。

临床怎么用

  • 作者结论为:AMBER 照护集的完全试验技术上可行但因资格标准操作化问题而不切实际,需考虑并测试替代研究方法。
  • 原文未据此给出临床推荐。

局限性

  • 对照臂招募困难:该臂筛查 728 例患者中 647 例(88.9%)被排除,妨碍了最佳招募。
  • 医护人员担忧干预资格标准的主观性、识别潜在患者需进行预后判断、知情同意程序及问卷长度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The AMBER (Assessment, Management, Best Practice, Engagement, Recovery Uncertain) care bundle is a complex intervention used in UK hospitals to support patients with uncertain recovery. However, it has yet to be evaluated in a randomised controlled trial (RCT) to identify potential benefits or harms. The aim of this trial was to investigate the feasibility of a cluster RCT of the AMBER care bundle. METHODS: This is a prospective mixed-methods feasibility cluster RCT. Quantitative data collected from patients (or proxies if patients lack capacity) were used (i) to examine recruitment, retention and follow-up rates; (ii) to test data collection tools for the trial and determine their optimum timing; (iii) to test methods to identify the use of financial resources; and (iv) to explore the acceptability of study procedures for health professionals and patients. Descriptive statistical analyses and thematic analysis used the framework approach. RESULTS: In total, 894 patients were screened, of whom 220 were eligible and 19 of those eligible (8.6%) declined to participate. Recruitment to the control arm was challenging. Of the 728 patients screened for that arm, 647 (88.9%) were excluded. Overall, 65 patients were recruited (81.3% of the recruitment target of 80). Overall, many were elderly (≥80 years, 46.2%, n = 30, mean = 77.8 years, standard deviation [SD] = 12.3 years). Over half (53.8%) had a non-cancer diagnosis, with a mean of 2.3 co-morbidities; 24.6% patients (n = 16) died during their hospital stay and 35.4% (n = 23) within 100 days of discharge. In both trial arms, baseline IPOS subscale scores identified moderate patient anxiety (control: mean 13.3, SD 4.8; intervention: mean 13.3, SD 5.1), and howRwe identified a good care experience (control: mean 13.1, SD 2.5; intervention: mean 11.5, SD 2.1). Collecting quantitative service use and quality of life data was feasible. No patient participants regarded study involvement negatively. Focus groups with health professionals identified concerns regarding (i) the subjectivity of the intervention's eligibility criteria, (ii) the need to prognosticate to identify potential patients and (iii) consent procedures and the length of the questionnaire. CONCLUSIONS: A full trial of the AMBER care bundle is technically feasible but impractical due to fundamental issues in operationalising the intervention's eligibility criteria, which prevents optimal recruitment. Since this complex intervention continues to be used in clinical care and advocated in policy, alternative research approaches must be considered and tested. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number (ISRCTN) Register, ISRCTN36040085 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Koffman J, Yorganci E, Yi D, et al. Managing uncertain recovery for patients nearing the end of life in hospital: a mixed-methods feasibility cluster randomised controlled trial of the AMBER care bundle. Trials. 2019. PMID: 31419994. doi:10.1186/s13063-019-3612-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。